Tips from Other Journals

Low-Dose Aspirin vs. Vitamin E in Cardiovascular Disease



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2001 Aug 15;64(4):661-665.

Low-dose aspirin and vitamin E have been advocated as preventive therapy in patients with risk factors for cardiovascular disease. The value of these interventions remains uncertain because their efficacy has not been conclusively demonstrated in communitybased studies. The Primary Prevention Project was designed to assess the effectiveness of aspirin and vitamin E in preventing cardiovascular events in adults with one or more risk factors for cardiovascular disease.

Participants 50 years and older were recruited through primary care practices in Italy. Patients were eligible for the study if they had at least one significant cardiovascular risk factor, such as age of 65 years or older; systolic blood pressure of 160 mm Hg or greater or diastolic blood pressure of 95 mm Hg or greater on at least three occasions; hypercholesterolemia; diabetes mellitus; obesity; or family history of myocardial infarction before the age of 55 in at least one parent or sibling. Patients with a poor short-term prognosis, those with contraindications to aspirin and those taking anticoagulants or anti-inflammatory agents were excluded from the study. Participants were randomly allocated to receive placebo, 100-mg entericcoated aspirin or 300-mg synthetic vitamin E daily. Patients were reviewed every four months for compliance and to assess symptoms, evidence of cardiovascular conditions or development of new risk factors.

About 4,500 patients and 15 hospital hypertension units were recruited for the study by 315 participating general practitioners. The mean age of the 2,583 women and 1,912 men was 64.4 years. In each group, about 30 percent of patients had one risk factor, and 40 percent had two risk factors for cardiovascular disease. The remaining patients had three or more risk factors. The most common risk factor was hypertension, which affected 68 percent of patients. With the exception of elevated cholesterol levels, the rate of which was slightly higher in patients treated with aspirin, the occurrence of hypertension and other risk factors was balanced across the treatment groups.

By the end of the study, 19 percent of patients assigned to aspirin and 13 percent of patients assigned to vitamin E had discontinued treatment. Side effects were cited as the principal reason for discontinuation by about 8 percent of the aspirin group and 1 percent of the vitamin E group. Follow-up of 3.6 years was achieved in 4,150 patients (92 percent). One percent of the aspirin group and 0.3 percent of the other patients developed bleeding complications, but three of the four deaths attributed to hemorrhage occurred in patients who were not treated with aspirin.

The accompanying table provides a profile of the effects of aspirin and vitamin E on the efficacy end points of the study. Aspirin therapy consistently lowered adverse cardiovascular outcomes, and the study was discontinued because of the strength of evidence supporting patient benefit from aspirin therapy. The reduction in all end points was most significant for that of cardiovascular death, the rate of which decreased from 1.4 to 0.8 percent, and for total cardiovascular events, the rate of which decreased from 8.2 to 6.3 percent. Patients taking vitamin E showed no advantage over those taking placebo with the exception of a 46 percent reduction in peripheral artery disease. Noncardiovascular events occurred equally in all groups.

Efficacy Profile of Aspirin and Vitamin E Treatment

End points Aspirin n = 2,226 (%) No aspirin n = 2,269 (%) Vitamin E n = 2,231 (%) No vitamin E n = 2,264 (%)

Main combined end point (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke)

45 (2.0)

64 (2.8)

56 (2.5)

53 (2.3)

Total cardiovascular events or diseases*

141 (6.3)

187 (8.2)

158 (7.1)`

170 (7.5)

All deaths

62 (2.8)

78 (3.4)

72 (3.2)

68 (3.0)

Cardiovascular

17 (0.8)

31 (1.4)

22 (1.0)

26 (1.1)

Noncardiovascular

45 (2.0)

47 (2.0)

50 (2.2)

42 (1.9)

All myocardial infarction

19 (0.8)

28 (1.2)

22 (1.0)

25 (1.1)

Nonfatal myocardial infarction

15 (0.7)

22 (1.0)

19 (0.8)

18 (0.8)

All stroke

16 (0.7)

24 (1.1)

22 (1.0)

18 (0.8)

Nonfatal stroke

15 (0.7)

18 (0.8)

20 (0.9)

13 (0.6)

Angina pectoris

54 (2.4)

67 (3.0)

66 (3.0)

55 (2.4)

Transient ischemic attack

28 (1.3)

40 (1.8)

33 (1.5)

35 (1.5)

Peripheral-artery disease

17 (0.8)

29 (1.3)

16 (0.7)

30 (1.3)

Revascularization procedure

20 (0.9)

29 (1.3)

27 (1.2)

22 (1.0)


*—Patients with one or more of the following events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, angina pectoris, transient ischemic attack, peripheral-artery disease, revascularization procedure.

Adapted with permission from Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:92.

Efficacy Profile of Aspirin and Vitamin E Treatment

View Table

Efficacy Profile of Aspirin and Vitamin E Treatment

End points Aspirin n = 2,226 (%) No aspirin n = 2,269 (%) Vitamin E n = 2,231 (%) No vitamin E n = 2,264 (%)

Main combined end point (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke)

45 (2.0)

64 (2.8)

56 (2.5)

53 (2.3)

Total cardiovascular events or diseases*

141 (6.3)

187 (8.2)

158 (7.1)`

170 (7.5)

All deaths

62 (2.8)

78 (3.4)

72 (3.2)

68 (3.0)

Cardiovascular

17 (0.8)

31 (1.4)

22 (1.0)

26 (1.1)

Noncardiovascular

45 (2.0)

47 (2.0)

50 (2.2)

42 (1.9)

All myocardial infarction

19 (0.8)

28 (1.2)

22 (1.0)

25 (1.1)

Nonfatal myocardial infarction

15 (0.7)

22 (1.0)

19 (0.8)

18 (0.8)

All stroke

16 (0.7)

24 (1.1)

22 (1.0)

18 (0.8)

Nonfatal stroke

15 (0.7)

18 (0.8)

20 (0.9)

13 (0.6)

Angina pectoris

54 (2.4)

67 (3.0)

66 (3.0)

55 (2.4)

Transient ischemic attack

28 (1.3)

40 (1.8)

33 (1.5)

35 (1.5)

Peripheral-artery disease

17 (0.8)

29 (1.3)

16 (0.7)

30 (1.3)

Revascularization procedure

20 (0.9)

29 (1.3)

27 (1.2)

22 (1.0)


*—Patients with one or more of the following events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, angina pectoris, transient ischemic attack, peripheral-artery disease, revascularization procedure.

Adapted with permission from Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:92.

The authors conclude that low-dose aspirin conferred significant benefit in patients at risk of cardiovascular events. In about 8,000 person-years of aspirin treatment, there was no excess risk of hemorrhagic cerebrovascular events. In contrast, patients taking vitamin E had no benefit and, in some end points, had worse results than patients taking placebo. The authors urge primary care physicians and public policy makers to promote the use of low-dose aspirin in patients with risk factors for cardiovascular disease.

ANNE D. WALLING, M.D.

Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. January 13, 2001;357:89–95.


Copyright © 2001 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article